Fenproporex and amphetamine pharmacokinetics in oral fluid after controlled oral administration of fenproporex

Therapeutic Drug Monitoring

Volumn 34, Issue 5, 2012, Pages 545-553

  Comiran, Eloisa ^a   Souza, Daniele Zago ^a,b   Boehl, Paula Otero ^a   De Cássia Mariotti, Kristiane ^a   Pechansky, Flavio ^c   Duarte, Paulina Do Carmo Arruda Vieira ^d   De Boni, Raquel Brandini ^c   Fröehlich, Pedro Eduardo ^a   Limberger, Renata Pereira ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Setor Técnico Científico Superintendência Regional   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d Secretaria Nacional de Políticas Sobre Drogas SENAD   (Brazil)

Author keywords

amphetamine; fenproporex; oral fluid; pharmacokinetics; solid phase microextraction

Indexed keywords

ADENOSINE PHOSPHATE; AMPHETAMINE; DEUTERIUM; FENPROPOREX;

ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SALIVA LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; MASS FRAGMENTOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; SELECTED ION MONITORING MODE; SOLID PHASE MICROEXTRACTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AMPHETAMINES; BODY FLUIDS; CENTRAL NERVOUS SYSTEM STIMULANTS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; MOUTH; SOLID PHASE MICROEXTRACTION; SUBSTANCE ABUSE DETECTION;

EID: 84866551411     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318263c6c5     Document Type: Article

References (54)

1. Bell RR, Crookham SB, Dunn WA, et al. A contemporaneous finding of fenproporex in a polydrug suicide. J Anal Toxicol. 2001;25:652-656.
2. Moffat AC, Osselton MD, Widdop B, eds. Clarke's Analysis of Drugs and Poisons. 3rd ed. London, United Kingdom: Pharmaceutical Press; 2004.
3. United Nations: International Narcotics Control Board. Report of the International Narcotics Control Board for 2009. New York, NY: United Nations; 2010.
4. Souza DZ, Boehl PO, Comiran E, et al. Which amphetamine-type stimulants can be detected by oral fluid immunoassays? Ther Drug Monit. 2012;34:98-109.
5. Food and Drug Administration (FDA). FDA warns consumers about Brazilian diet pills found to contain active drug ingredients: Emagrece sim and herbathin dietary supplements may be harmful. Available at: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2006/ucm108578.htm?utm-source=fdaSearch&utm- medium=website&utm-term=fenproporex&utm-content=3. Accessed March, 2012.
6. Food and Drug Administration (FDA). FDA uncovers additional tainted weight loss products: Agency alerts consumers to the finding of new undeclared drug ingredients. Available at: http://www.fda.gov/News Events/Newsroom/ PressAnnouncements/2009/ucm149547.htm?utm-source= fdaSearch&utm-medium= website&utm-term=fenproporex&utm-content=4. Accessed March, 2012.
7. Wendler EA, Busato CR, Miyoshi E. The use of amphetamines by truck drivers in order to reduce sleep [in Portuguese]. Publ UEPG Ci Biol Saude (Ponta Grossa). 2003;9:7-14.
8. Souza JC, Paiva T, Reimão R. Sleep habits, sleepiness and accidents among truck drivers. Arq Neuropsiquiatr. 2005;63:925-930.
9. Nascimento EC, Nascimento E, Silva Jde P. Alcohol and amphetamines use among long-distance truck drivers [in Portuguese]. Rev Saude Pub-lica. 2007;41:290-293.
10. Moreira RS, Gadani JA. The prevalence of use of amphetamines by truckers passing through Dourados-MS city. Interbio. 2009;3:27-34.
11. Kraemer T, Theis GA, Weber AA, et al. Studies on the metabolism and toxicological detection of the amphetamine-like anorectic fenproporex in human urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. J Chromatogr B Biomed Sci Appl. 2000;738:107-118.
12. Cody JT, Valtier S. Detection of amphetamine following administration of fenproporex. J Anal Toxicol. 1996;20:425-431.
13. Musshoff F. Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine. Drug Metab Rev. 2000;32:15-44. Review.
14. United Nations: United Nations Office on Drugs and Crime. Guidelines for Testing Drugs Under International Control in Hair, Sweat and Saliva. New York, NY: United Nations; 2001.
15. Wille SM, Raes E, Lillsunde P, et al. Relationship between oral fluid and blood concentrations of drugs of abuse in drivers suspected of driving under the influence of drugs. Ther Drug Monit. 2009;31:511-519.
16. Toennes SW, Kauert GF, Steinmeyer S, et al. Driving under the influence of drugs-evaluation of analytical data of drugs in oral fluid, serum and urine, and correlation with impairment symptoms. Forensic Sci Int. 2005; 152:149-155.
17. Pehrsson A, Gunnar T, Engblom C, et al. Roadside oral fluid testing: comparison of the results of drugwipe 5 and drugwipe benzodiazepines on-site tests with laboratory confirmation results of oral fluid and whole blood. Forensic Sci Int. 2008;175:140-148.
18. Drobitch RK, Svensson CK. Therapeutic drug monitoring in saliva. An update. Clin Pharmacokinet. 1992;23:365-379. Review.
19. Pichini S, Altieri I, Zuccaro P, et al. Drug monitoring in nonconventional biological fluids and matrices. Clin Pharmacokinet. 1996;30:211-228. Review.
20. Kintz P, Samyn N. Use of alternative specimens: drugs of abuse in saliva and doping agents in hair. Ther Drug Monit. 2002;24:239-246. Review.
21. Yonamine M. Saliva as Biological Specimen for Screening the Use of Alcohol, Amphetamine, Methamphetamine, Cocaine and Marijuana by Professional Drivers. [in Portuguese; habilitation thesis]. São Paulo, Brazil: University of São Paulo; 2004.
22. Drummer OH. Drug testing in oral fluid. Clin Biochem Rev. 2006;27:147-159.
23. Standards Australia. AS 4760-2006 Procedures for Specimen Collection and the Detection and Quantification of Drugs in Oral Fluid. Sydney, Australia: Standards Australia; 2006.
24. Biermann T, Schwarze B, Zedler B, et al. On-site testing of illicit drugs: the use of the drug-testing device "Toxiquick". Forensic Sci Int. 2004; 143:21-25.
25. Gustavsen I, Mørland J, Bramness JG. Impairment related to blood amphetamine and/or methamphetamine concentrations in suspected drugged drivers. Accid Anal Prev. 2006;38:490-495.
26. Gjerde H, Verstraete A. Can the prevalence of high blood drug concentrations in a population be estimated by analysing oral fluid? A study of tetrahydrocannabinol and amphetamine. Forensic Sci Int. 2010;195:153-159.
27. Aps JK, Martens LC. Review: the physiology of saliva and transfer of drugs into saliva. Forensic Sci Int. 2005;150:119-131. Review.
28. Crouch DJ. Oral fluid collection: the neglected variable in oral fluid testing. Forensic Sci Int. 2005;150:165-173. Review.
29. Cone EJ, Huestis MA. Interpretation of oral fluid tests for drugs of abuse. Ann N Y Acad Sci. 2007;1098:51-103. Review.
30. Huestis MA, Cone EJ. Methamphetamine disposition in oral fluid, plasma, and urine. Ann N Y Acad Sci. 2007;1098:104-121.
31. Schepers RJ, Oyler JM, Joseph RE Jr, et al. Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers. Clin Chem. 2003;49:121-132.
32. de la Torre R, Farré M, Navarro M, et al. Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices. Clin Pharmacokinet. 2004;43:157-185. Review.
33. Drummer OH. Review: pharmacokinetics of illicit drugs in oral fluid. Forensic Sci Int. 2005;150:133-142. Review.
34. Verstraete AG. Oral fluid testing for driving under the influence of drugs: history, recent progress and remaining challenges. Forensic Sci Int. 2005; 150:143-150. Review.
35. Marchei E, Farrè M, Pellegrini M, et al. Pharmacokinetics of methylphe-nidate in oral fluid and sweat of a pediatric subject. Forensic Sci Int. 2010;196:59-63.
36. Walsh JM, Verstraete AG, Huestis MA, et al. Guidelines for research on drugged driving. Addiction. 2008;103:1258-1268.
37. Cody JT, Valtier S, Stillman S. Amphetamine and fenproporex levels following multidose administration of fenproporex. J Anal Toxicol. 1999; 23:187-194.
38. Souza DZ, Boehl PO, Comiran E, et al. Determination of amphetamine-type stimulants in oral fluid by solid-phase microextraction and gas chromatography-mass spectrometry. Anal Chim Acta. 2011;696:67-76.
39. Fagiolino P. Monitorización de Fármacos em Saliva: Aplicaciones Bio-farmacéuticas, Farmacocinéticas y Terapéuticas. Montevideo, Uruguay: Comisión Sectorial de Investigación Científica de la Universidad de la República; 1999.
40. Dickson S, Park A, Nolan S, et al. The recovery of illicit drugs from oral fluid sampling devices. Forensic Sci Int. 2007;165:78-84.
41. Seyffart G. Drug Dosage in Renal Insufficiency. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1991.
42. Huestis MA, Cone EJ. Alternative testing matrices. In: Karch SB, ed. Drug Abuse Handbook. Boca Raton, FL: CRC Press; 1998.
43. Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit. 2004;26:200-205. Review.
44. Kraemer T, Pflugmann T, Bossmann M, et al. Fenproporex N-dealkylation to amphetamine-enantioselective in vitro studies in human liver microsomes as well as enantioselective in vivo studies in Wistar and Dark Agouti rats. Biochem Pharmacol. 2004;68:947-957.
45. Moore CM. Drugs of abuse in oral fluid. In: Ropero-Miller JD, Goldberger BA, Liu RH, eds. Handbook of Workplace Testing. 2nd ed. Washington, DC: American Association for Clinical Chemistry; 2009.
46. Affiniton, Inc. Drugwipe®: technical specifications [online]. Available at: http://www.affiniton.com/drugwipeInserts.pdf. Accessed August, 2010.
47. Concateno plc. Cozart® DDS 806 Drug Detection System CGP7189: technical specifications. Available at: http://www.concateno.com/ddme-cms/ userfiles/files/technical-specifications/CGP7189%20Cozart%20DDS% 20806%20Technical%20Specification%2014JUL09.pdf Accessed August, 2010.
48. Dräger Safety AG & Co. KGaA. Dräger DrugTest® 5000 Test Kit: product information [online]. Available from at: http://www.draeger.com/ media/10/08/41/10084108/drugtest-test-kits-pi-en-us.pdf Accessed August, 2010.
49. Dräger Safety AG & Co. KGaA. Dräger DrugTest® 5000-Cross Reactivity Chart: Technical Information Sent by the Manufacturer. Lübeck, Germany: Dräger; 2010.
50. Dräger Safety AG & Co. KGaA. Dräger DrugCheck™ Specificity Study Summary and Dräger DrugCheck™ Cross Reactivity Study Summary: Technical Information Sent by the Manufacturer. Lübeck, Germany: Dräger; 2005.
51. Blencowe T, Pehrsson A, Lillsunde P, eds. Analytical evaluation of oral fluid screening devices and preceding selection procedures. Available at: http://www.druid-project.eu/nn-107548/Druid/EN/deliverales-list/downloads/ Deliverable-3-2-2, templateId=raw, property=publicationFile.pdf/Deliverable-3-2- 2.pdf. Accessed March, 2010.
52. Immunalysis Corporation, Inc. Amphetamine Elisa Kit for Oral Fluids [package insert]. Pomona, CA: Immunalysis Corporation, Inc; 2005.
53. Immunalysis Corporation, Inc. Methamphetamine Elisa Kit for Oral Fluids [Package Insert]. Pomona, CA: Immunalysis Corporation, Inc; 2005.
54. Alfa Scientific Designs, Inc. Oral-ViewTM Saliva Multi-Drug of Abuse Test. Revision E 030409 [Package Insert]. Poway, CA: Alfa Scientific Designs, Inc; 2009.